Relevant bibliographies by topics / Paradoxical Psoriasis

Academic literature on the topic 'Paradoxical Psoriasis'

Author: Grafiati
Published: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Paradoxical Psoriasis.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Paradoxical Psoriasis"

1

Vender, Reid, and Ronald Vender. "Paradoxical, Cupping-Induced Localized Psoriasis: A Koebner Phenomenon." Journal of Cutaneous Medicine and Surgery 19, no. 3 (March 13, 2015): 320–22. http://dx.doi.org/10.2310/7750.2014.14109.

Full text
Abstract:
Background Cupping therapy is a traditional Chinese medicine used to heal psoriasis. The Koebner phenomenon is the occurrence of psoriatic lesions at the site of cutaneous injury. Objective To describe the first case of biopsy-proven cupping-induced localized psoriasis, an example of the Koebner phenomenon. Methods The histopathology of the lesions is described. A brief review of the literature regarding cupping therapy and its efficacy are discussed. Results A 45-year-old Asian male presented himself to the dermatology clinic for further treatment of his psoriasis. Four unusually circular plaques on the lower back were discovered. Pathologic diagnosis revealed an early lesion of psoriasis. on further inquiry, the patient admitted to undergoing a recent ‘'cupping'’ procedure in an attempt to cure his condition. Conclusion The efficacy of cupping therapy is controversial, and psoriatic patients may develop localized psoriasis through koebnerization as a result of cupping therapy rather than achieve desirable therapeutic benefits.
APA, Harvard, Vancouver, ISO, and other styles
2

Bucalo, Agostino, Federica Rega, Arianna Zangrilli, Valentina Silvestri, Virginia Valentini, Giorgia Scafetta, Federica Marraffa, et al. "Paradoxical Psoriasis Induced by Anti-TNFα Treatment: Evaluation of Disease-Specific Clinical and Genetic Markers." International Journal of Molecular Sciences 21, no. 21 (October 23, 2020): 7873. http://dx.doi.org/10.3390/ijms21217873.

Full text
Abstract:
Paradoxical psoriasis (PP) may occur during treatment with anti-tumor necrosis factor-alpha (TNF-α) drugs in various chronic immune-mediated diseases, mainly inflammatory bowel diseases (IBD) and psoriasis. In this study, clinical and genetic characteristics of PP arising in IBD and psoriatic patients were investigated to identify disease-specific markers of the paradoxical effect. A total of 161 IBD and psoriatic patients treated with anti-TNF-α drugs were included in the study. Of these patients, 39 developed PP. All patients were characterized for the main clinical–pathologic characteristics and genotyped for six candidate single nucleotide polymorphisms (SNPs) selected for their possible role in PP susceptibility. In IBD patients, the onset of PP was associated with female sex, presence of comorbidities, and use of adalimumab. IBD patients with PP had a higher frequency of the TNF-α rs1799964 rare allele (p = 0.006) compared with cases without the paradoxical effect, and a lower frequency of the human leucocyte antigen (HLA)-Cw06 rs10484554 rare allele (p = 0.03) compared with psoriatic patients with PP. Overall, these findings point to specific clinical and genetic characteristics of IBD patients with PP and provide data showing that genetic variability may be related to the paradoxical effect of anti-TNF-α drugs with possible implications into clinical practice.
APA, Harvard, Vancouver, ISO, and other styles
3

Giovanna Brunasso, Alexandra Maria, and Cesare Massone. "Paradoxical Psoriasis During IL-17 Blockage: Two Memorable Patients." Dermatology and Dermatitis 6, no. 2 (August 13, 2021): 01–02. http://dx.doi.org/10.31579/2578-8949/080.

Full text
Abstract:
47 year-old man who suffered for plaque psoriasis since 2013 was previously treated with topicals, UVB photherapy, acitretin, methotrexate and adalimumab (Imraldi®) with scarce response. Brodalumab (IL-17 receptor chain A blocking antibody) at 210 mg sc day 0, week-1, week-2 and every 2 weeks was initiated (baseline PASI of 16) with fast improvement of psoriasis (PASI-90 at week 4) and new onset of erythema, pustules and pain in the palmoplantar area after each subcutaneous Brodalumab administration and progressive improvement after 5-8 days.
APA, Harvard, Vancouver, ISO, and other styles
4

ZEKEY, Emre, Pinar KARABAGLİ, and Gülcan SAYLAM KURTİPEK. "Adalimumab induced severe paradoxical psoriasis in a patient with ankylosing spondylitis." Cukurova Medical Journal 47, no. 4 (December 28, 2022): 1768–70. http://dx.doi.org/10.17826/cumj.1170774.

Full text
Abstract:
Anti-tumor necrosis factor (Anti-TNF)’s have been used frequently in rheumatology and dermatology. These drugs may couse psoriasiform lesions paradoxically. In this report, ankylosing spondylitis patient who developed severe paradoxical psoriasis while being treated with adalimumab was discussed.
APA, Harvard, Vancouver, ISO, and other styles
5

Alaou, Rhita, Sofia Alami, Nawal Lagdali, Maryeme Kadiri, Camélia Berhili, Fatima-Zahra Chabib, Mohamed Borahma, Imane Benelbarhdadi, and Fatima-Zahra Ajana. "Paradoxical cutaneous manifestations induced by TNF inhibitors in patients with inflammatory bowel disease." Our Dermatology Online 14, no. 1 (January 2, 2023): 60–64. http://dx.doi.org/10.7241/ourd.20231.12.

Full text
Abstract:
Background: Anti-TNF drugs have revolutionized the management of numerous inflammatory diseases, yet they may produce paradoxical effects. Materials and Methods: A descriptive study was conducted on patients with chronic inflammatory bowel disease (IBD) on anti-TNF therapy who had developed paradoxical psoriasis. Results: Out of a total of 218 patients followed for IBD on TNF inhibitors, five presented with paradoxical psoriasis. In four patients, a specific treatment for psoriasis was associated with anti-TNF treatment. In one patient, a swap to ustekinumab was decided. Good progress was noted in four patients. In one, there was no improvement of the psoriasis on methotrexate, which was switched to another anti-TNF agent. Conclusion: In our experience, TNF inhibitor-induced psoriasis is relatively rare (prevalence of 2.3%). The choice of treatment is reached by assessing the benefit-risk balance. Key words: Paradoxical cutaneous manifestations; TNF inhibitors; Cutaneous manifestations; Inflammatory bowel disease
APA, Harvard, Vancouver, ISO, and other styles
6

McFeely, O., E. Pender, L. Victory, H. Almutlaq, and E. Storan. "Risankizumab‐induced paradoxical pustular psoriasis." Clinical and Experimental Dermatology 47, no. 3 (December 10, 2021): 616–17. http://dx.doi.org/10.1111/ced.15006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Dogra, S., A. Bishnoi, T. Narang, and S. Handa. "Secukinumab-induced paradoxical pustular psoriasis." Clinical and Experimental Dermatology 44, no. 1 (August 20, 2018): 72–73. http://dx.doi.org/10.1111/ced.13731.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Boch, Katharina, Detlef Zillikens, Ralf J. Ludwig, and Diamant Thaçi. "Paradoxical improvement of life quality in the COVID-19 era in psoriasis patients." PLOS ONE 17, no. 9 (September 27, 2022): e0275293. http://dx.doi.org/10.1371/journal.pone.0275293.

Full text
Abstract:
Background Psoriasis is a chronic immune-mediated inflammatory disease. Beyond the physical dimensions, the disease has an extensive emotional and psychosocial effect on patients, influencing their quality of life, social life and interpersonal relationships. Thus patient-reported outcomes are a crucial instrument for the evaluation of disease burden. Navigating life in times of the COVID-19 pandemic is challenging, especially for persons suffering from chronic diseases. We here analyzed the impact of lockdown restrictions on psoriasis patients. Objective To compare the Dermatology Life Quality Index (DLQI) before and during the COVID-19 pandemic of patients with psoriasis. Methods Retrospective longitudinal analysis in adult patients with moderate to severe psoriasis undergoing biologic treatment between January 2020 and January 2021. DLQI, patient demographics, Psoriasis Area and Severity Index (PASI), and recent biologic treatment were recorded. Results 103 patients were identified, of whom 19 had additional psoriatic arthritis. Female (n = 29) and male (n = 74) patients were distributed 1 to 3. Median age of patients was 54 years (range 18–85). All patients received biologic systemic treatment: anti-IL-23 (n = 39), anti-IL-17A (n = 30), anti-IL-12/23 (n = 25), or anti-TNFα (n = 9). Comparing DLQI scores before the COVID-19 pandemic and under lockdown restriction showed improved DLQI scores over time. Further analysis displayed that patients mostly ticked “not relevant” on social activities during lockdown. Thus, the DLQI scores may be artificial improved and may not really reflect the actual disease burden. Conclusions Psoriasis patients showed a contrary improvement of life quality despite harsh COVID-19 lockdown suggesting that DLQI should be modified when social life is restricted.
APA, Harvard, Vancouver, ISO, and other styles
9

Ürün, Yıldız Gürsel, Hande Yelgen, Mustafa Ürün, and Nuray Can. "Secukinumab-induced paradoxical palmoplantar pustular psoriasis." TURKDERM 56, no. 4 (December 31, 2022): 197–99. http://dx.doi.org/10.4274/turkderm.galenos.2022.39591.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Megna, Matteo, Sonia Sofia Ocampo-Garza, Luca Potestio, Giuseppina Fontanella, Lucia Gallo, Sara Cacciapuoti, Angelo Ruggiero, and Gabriella Fabbrocini. "New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?" Biomedicines 9, no. 10 (October 15, 2021): 1482. http://dx.doi.org/10.3390/biomedicines9101482.

Full text
Abstract:
Psoriasis and psoriatic arthritis (PsA) development is sustained by tumor necrosis factor (TNF)α, interleukin (IL)17, and IL23; hence, biologics targeting those cytokines represent useful therapeutic weapons for both conditions. Nevertheless, biologics strongly reduce PsA risk; several studies reported the possibility of new-onset PsA during biologic therapy for psoriasis. The aim of this 1-year prospective study is to evaluate the prevalence of paradoxical PsA in psoriasis patients under biologic therapy and review the existing literature. For each patient, age, sex, psoriasis duration, psoriasis severity, comorbidities, and previous and current psoriasis treatments were collected, and each subject was screened for PsA using the Early ARthritis for Psoriatic patient (EARP) questionnaire every 3 months for 1 year. New-onset PsA was diagnosed in 10 (8.5%) out of 118 patients (three male, 30.0%; mean age 44.5 years) involving every different biologic class (anti-TNF, anti-IL12/23, anti-IL17, and anti-IL23). No significant risk factor for new-onset PsA was identified; no significant difference was found comparing patients who developed PsA and subjects who did not develop PsA regarding psoriasis severity, past/current therapies, and comorbidities. Clinicians must keep in mind the possibility of PsA onset also in patients undergoing biologics so that PsA screening should be strongly recommended at each follow-up.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Paradoxical Psoriasis"

1

Ayala-Fontanez, Nilmarie. "Paradoxical onset of psoriasis after IL-6 receptor blockade." Case Western Reserve University School of Graduate Studies / OhioLINK, 2015. http://rave.ohiolink.edu/etdc/view?acc_num=case1436396399.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Paradoxical Psoriasis"

1

Morelli, Martina, Claudia Scarponi, Stefania Madonna, and Cristina Albanesi. "Experimental Methods for the Immunological Characterization of Paradoxical Psoriasis Reactions Induced by TNF-α Biologics." In Methods in Molecular Biology, 155–65. New York, NY: Springer US, 2020. http://dx.doi.org/10.1007/978-1-0716-1130-2_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Paradoxical Psoriasis"

1

Ruwaard, J., E. van der Vlugt, P. Brevet, L. Berkhout, T. Rispens, M. Nurmohamed, and GJ Wolbink. "FRI0707 Drug levels and antidrug antibodies in the development of paradoxical psoriasis and palmoplantar pustulosis." In Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.3635.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Nikishina, I., O. Kostareva, M. Kaleda, S. Rodionovskaya, S. Arsenyeva, D. Alekseev, E. Fedorov, and A. Shapovalenko. "AB0955 New onset of uveitis, psoriasis or ibd as paradoxical effects of biologics in patients with juvenile idiopathic arthritis: single center experience." In Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.6753.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Paradoxical Psoriasis' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography